Recombinant Human CD26 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0834
Recombinant Human CD26 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0834
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | Fc |
Host Species | Human |
Accession | NP_001926.2 |
Synonym | ADABP, ADCP2, CD26, DPPIV, TP103 |
Background | Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes. |
Description | A DNA sequence encoding the extracellular domain (Asn 29-Pro 766) of the mature form of human DPPIV (NP_001926.2) was expressed with the fused Fc region of human IgG1 at the N-terminus. |
Source | HEK293 |
Predicted N Terminal | Glu 20 |
AA Sequence | Asn 29-Pro 766 |
Molecular Weight | The recombinant human Fc/DPPIV is a disulfide-linked homodimeric protein.The reduced monomer consists of 975 a.a. and has a predicted molecular mass of 112 kDa. As a result of glycosylation, the apparent molecular mass of rhFc/DPPIV monomer is approximately 120-130 kDa in SDS-PAGE under reducing conditions. |
Purity | >95% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | 1. Measured by its ability to bind recombinant Cynomolgus CXCL12 in a functional ELISA.2. Measured by its ability to bind recombinant Human SDF1b in a functional ELISA.3. Using the Octet RED System, the affinity constant (Kd) of human Fc-DPPIV bound to Spike (HCoV-EMC/2012) was 11 nM.4. Using the Octet RED System, the affinity constant (Kd) of human Fc-DPPIV bound to Spike (HCoV-EMC/2012) was 32 nM.5. Using the Octet RED System, the affinity constant (Kd) of human Fc-DPPIV bound to Spike (HCoV-EMC/2012) (ECD, aa 1-1297) was 43 nM.6. Using the Octet RED System, the affinity constant (Kd) of human Fc-DPPIV bound to Spike-His (aa 1-760) was 12 nM. |
Formulation | Lyophilized from sterile PBS, pH 7.4. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |